Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients.
about
Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopeniaAdvances in Diagnosis and Treatments for Immune ThrombocytopeniaCurrent Management of Primary Immune ThrombocytopeniaImmune thrombocytopeniaContemporary management of primary immune thrombocytopenia in adultsRisk of Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia Among 120 908 US Veterans With Hepatitis C Virus InfectionA systematic evaluation of laboratory testing for drug-induced immune thrombocytopeniaLaparoscopic splenectomy for primary immune thrombocytopenia: Current status and challengesAdvances in ITP--therapy and quality of life--a patient surveyThromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis.Splenectomy for adult chronic idiopathic thrombocytopenic purpura: experience from a single center in China.Management of patients with refractory immune thrombocytopenic purpura.Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi-center prospective study.Treatment of chronic immune thrombocytopenic purpura: the patients' perspective.Partial splenic embolization.Rituximab in the treatment of autoimmune haematological disorders.Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia.Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research DatabaseIdentifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods.Long-term management of chronic immune thrombocytopenic purpura in adults.Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.ITP: a historical perspective.Immune thrombocytopenia: no longer 'idiopathic'.Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults.Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study.Ischemic stroke in the setting of chronic immune thrombocytopenia in an elderly patient--a therapeutic dilemma.Prevalence of diagnosed adult immune thrombocytopenia in the United Kingdom.Therapeutic options for immune-mediated thrombocytopenia.[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].Risk and prognosis of adult primary immune thrombocytopenia.Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopeniaDiagnosis and management of maternal thrombocytopenia in pregnancy.Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?Total remission of severe immune thrombocytopenia after short term treatment with romiplostim.Prevalence of primary immune thrombocytopenia in Oklahoma.Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China.Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia
P2860
Q25257298-D67F6E67-2847-45F2-AC84-80459EB8C247Q26738630-759D041D-26BD-4E37-B276-4F1F03A8C61CQ26779408-9CE3C2BB-8F0A-40AD-8AC3-5514556DCF7AQ26830918-F093A663-B143-4836-8FAC-CE12E01A606AQ26853680-5A8792F1-F6D6-4FED-ACBE-6B5FCFAA5961Q27490427-7A167605-44A5-4EE4-B8A2-5D40A254B6A0Q27686838-664ABC55-28D2-412F-A600-74F37B2085F8Q28066579-8D4F7A5B-1769-4D3C-BC07-F4B4DCE1EAA8Q28742871-414CA035-F214-4F92-A409-1CAFA5AF9DF1Q30250259-B59CA01A-AE4C-4D21-B743-892856C01698Q33368706-43D14EB6-807C-40DC-BC2B-5878BE0E22AEQ33372113-D034ADEB-E69B-4336-9F5B-4808BE35660DQ33372582-6809DCBF-E8AD-4EA3-AAEA-904A5EA2DC26Q33374397-AB7446F4-1E20-4F69-870E-E7BE76C98094Q33377537-BC47CF87-1BFC-40AA-A5B6-80C76CE42618Q33378854-13391680-8F73-4AA9-A43F-14B1EE641F9CQ33386494-68CE46ED-DDAD-4C53-9C43-97562C025D4DQ33387498-35B5DCCF-CC60-466D-9AD4-DAD5600B57C2Q33388213-0FBCCE34-7A33-47B4-B3E3-8B7D43297BA0Q33389987-77AC1E13-F7A2-427D-892E-D02896390B02Q33392610-04B50393-43F2-4F87-8742-1464877130CCQ33392852-08D7F217-5ACB-43EC-81C4-94CCF53C9811Q33394791-8772A3F4-7EC2-4571-A0C1-D3F9A3503F80Q33395624-9E6C362E-5473-4522-8F63-D14A7D3123A9Q33396252-7E9C0620-F367-4A1A-97F7-2259183FA39BQ33396286-07EDC776-5DBB-4410-84C8-27C517AE76DAQ33397388-A5BECEFB-7D8F-4457-8362-D1249FFAA249Q33398252-13C4007D-F3D1-49E2-9440-A71D11608C25Q33398568-50387B16-F87B-4DF6-B9FA-9E2EE554ECFEQ33399601-09268389-105F-45F1-BF74-A6BBA496A3AAQ33400018-32ED3EE9-6528-4390-9AEF-5526D28A77EBQ33400566-05C2CF8F-80B0-4321-BA84-D213CBC58AD1Q33400612-61D7C115-0A2E-41C3-9030-D22DADA66B8FQ33400722-6671AA31-FDB1-4903-9555-B45F86516344Q33401045-F2C86845-D645-4458-A98C-47BE161C20C9Q33401130-A967A6E5-2B64-4A84-9DD3-30C54EBC1207Q33401252-B7971B77-46CD-4BE4-B334-1E7FA361735AQ33401671-908569C8-32C0-4639-B89A-F32DA272009AQ33403176-9E1F3B26-A4D0-4663-949B-98F8DA9B95CFQ33407451-15130D97-03D2-4127-A042-ED410BB03E5B
P2860
Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinically significant newly p ...... -based cohort of 245 patients.
@ast
Clinically significant newly p ...... -based cohort of 245 patients.
@en
type
label
Clinically significant newly p ...... -based cohort of 245 patients.
@ast
Clinically significant newly p ...... -based cohort of 245 patients.
@en
prefLabel
Clinically significant newly p ...... -based cohort of 245 patients.
@ast
Clinically significant newly p ...... -based cohort of 245 patients.
@en
P2093
P2860
P1476
Clinically significant newly p ...... -based cohort of 245 patients.
@en
P2093
Annette J Neylon
Martin R Howard
Northern Region Haematology Group
Penelope R A Taylor
Peter W G Saunders
Stephen J Proctor
P2860
P304
P356
10.1046/J.1365-2141.2003.04547.X
P407
P577
2003-09-01T00:00:00Z